BIOMAT Database Logo BIOMAT Database Logo

Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys. 1993

A M Graybiel, and R Moratalla, and B Quinn, and L E DeLanney, and I Irwin, and J W Langston
Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, Cambridge 02139.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008454 Mazindol Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. AN-448,Diestet,Mazanor,Mazindole,Sanjorex,Sanorex,Solucaps,Teronac,Teronak,AN448
D009434 Neural Pathways Neural tracts connecting one part of the nervous system with another. Neural Interconnections,Interconnection, Neural,Interconnections, Neural,Neural Interconnection,Neural Pathway,Pathway, Neural,Pathways, Neural
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D011699 Putamen The largest and most lateral of the BASAL GANGLIA lying between the lateral medullary lamina of the GLOBUS PALLIDUS and the EXTERNAL CAPSULE. It is part of the neostriatum and forms part of the LENTIFORM NUCLEUS along with the GLOBUS PALLIDUS. Nucleus Putamen,Nucleus Putamens,Putamen, Nucleus,Putamens,Putamens, Nucleus
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D001931 Brain Mapping Imaging techniques used to colocalize sites of brain functions or physiological activity with brain structures. Brain Electrical Activity Mapping,Functional Cerebral Localization,Topographic Brain Mapping,Brain Mapping, Topographic,Functional Cerebral Localizations,Mapping, Brain,Mapping, Topographic Brain
D002421 Caudate Nucleus Elongated gray mass of the neostriatum located adjacent to the lateral ventricle of the brain. Caudatus,Nucleus Caudatus,Caudatus, Nucleus,Nucleus, Caudate
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine

Related Publications

A M Graybiel, and R Moratalla, and B Quinn, and L E DeLanney, and I Irwin, and J W Langston
Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys.
November 2010, PloS one,
A M Graybiel, and R Moratalla, and B Quinn, and L E DeLanney, and I Irwin, and J W Langston
Relation between brain dopamine loss and D2 dopamine receptor density in MPTP monkeys.
March 1988, Neuroscience letters,
A M Graybiel, and R Moratalla, and B Quinn, and L E DeLanney, and I Irwin, and J W Langston
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.
January 1995, Journal of neural transmission. Parkinson's disease and dementia section,
A M Graybiel, and R Moratalla, and B Quinn, and L E DeLanney, and I Irwin, and J W Langston
Loss of asymmetric spine synapses in prefrontal cortex of motor-asymptomatic, dopamine-depleted, cognitively impaired MPTP-treated monkeys.
May 2013, The international journal of neuropsychopharmacology,
A M Graybiel, and R Moratalla, and B Quinn, and L E DeLanney, and I Irwin, and J W Langston
In vivo binding of the dopamine uptake inhibitor [18F]GBR 13119 in MPTP-treated C57BL/6 mice.
January 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology,
A M Graybiel, and R Moratalla, and B Quinn, and L E DeLanney, and I Irwin, and J W Langston
Early Paradoxical Increase of Dopamine: A Neurochemical Study of Olfactory Bulb in Asymptomatic and Symptomatic MPTP Treated Monkeys.
January 2017, Frontiers in neuroanatomy,
A M Graybiel, and R Moratalla, and B Quinn, and L E DeLanney, and I Irwin, and J W Langston
SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys.
January 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
A M Graybiel, and R Moratalla, and B Quinn, and L E DeLanney, and I Irwin, and J W Langston
Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys.
February 2009, Experimental neurology,
A M Graybiel, and R Moratalla, and B Quinn, and L E DeLanney, and I Irwin, and J W Langston
Early Changes in Saccadic Eye Movement in Hemiparkinsonian MPTP-Treated Monkeys.
January 2015, Perception,
A M Graybiel, and R Moratalla, and B Quinn, and L E DeLanney, and I Irwin, and J W Langston
Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT.
April 1994, Experimental neurology,
Copied contents to your clipboard!